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Abstract
Polyunsaturated fatty acids (PUFA) have shown efficacy in the treatment of bipolar disorder, however their specific role in
treating the illness is unclear. Serum PUFA and dietary intakes of PUFA associate with suicidal behavior in epidemiological
studies. The objective of this study was to assess serum n-3 and n-6 PUFA levels in bipolar subjects and determine possible
associations with suicidal risk, including suicidal history and relevant personality factors that have been associated with
suicidality. We studied 27 bipolar subjects using the NEO-PI to assess the big five personality factors, structured interviews
to verify diagnosis and assess suicidal history, and lipomics to quantify n-3 and n-6 PUFA in serum. We found positive
associations between personality factors and ratios of n-3 PUFA, suggesting that conversion of short chain to long chain n-
3s and the activity of enzymes in this pathway may associate with measures of personality. Thus, ratios of docosahexaenoic
acid (DHA) to alpha linolenic acid (ALA) and the activity of fatty acid desaturase 2 (FADS2) involved in the conversion of ALA
to DHA were positively associated with openness factor scores. Ratios of eicosapentaenoic acid (EPA) to ALA and ratios of
EPA to DHA were positively associated with agreeableness factor scores. Finally, serum concentrations of the n-6,
arachidonic acid (AA), were significantly lower in subjects with a history of suicide attempt compared to non-attempters.
The data suggest that specific lipid profiles, which are controlled by an interaction between diet and genetics, correlate with
suicidal history and personality factors related to suicidal risk. This study provides preliminary data for future studies to
determine whether manipulation of PUFA profiles (through diet or supplementation) can affect personality measures and
disease outcome in bipolar subjects and supports the need for further investigations into individualized specific
modulations of lipid profiles to add adjunctive value to treatment paradigms.
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Introduction
Bipolar Illness strikes approximately 5.7 million adults in the
United States, or about 1–2% of the adult population in any given
year [1]. Importantly, the lifetime prevalence of suicide attempts in
bipolar patients is over 30% [2], making uncontrolled bipolar
disorder a large risk factor for suicidal behavior. In spite of the
plethora of medications used to manage bipolar disease, including
60 years of clinical use of lithium, the majority of treated bipolar
patients have ‘‘less than a satisfactory outcome’’ [3].
Several potential risk factors have been linked to suicidal
behavior. Two of these include personality factors and PUFA
serum levels. It is unknown whether PUFA serum levels are
associated with personality factors and if these may interact to
affect suicidal behavior. However, several studies suggest that low
serum n-3 PUFA associate with aggressive and violent behavior.
For example, n-3 PUFA have been found to be lower in suicide
attempters [4] and violent suicides correlate with seasonal
variation in n-3 intake [5]. Also, serum n-3 PUFA levels predict
serotonin and dopamine metabolites in cerebrospinal fluid that
differ between violent and non-violent subjects [6].
Supplementation with the long-chain n-3 (n-3) fatty acids,
docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA),
either as stand alone or adjunctive therapies have shown efficacy
in the treatment of bipolar disorder. However, results across
studies are inconsistent and the role of n-3s in the treatment of
bipolar disorder is unclear. A 2008 review by Turnbull et al.
surveyed clinical trials that used n-3s to treat bipolar disorder [7].
From over 100 publications, seven high quality and well-controlled
trials were identified, of which four found positive mood
improvements, two found no mood improvements and one did
not report on mood improvements following n-3 supplementation.
Therefore, while data is promising there remains ambiguity in the
field. One factor not considered in the trials to date is the
concentration of n-6 (n-6) fatty acids, which play complex
physiological roles in both health benefit and pro-inflammatory
state and are known to compete with n-3 fatty acids in many
cellular processes, and therefore should be considered.
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e29297Evidence for the involvement of n-3 and n-6 fatty acids in
bipolar disorder comes from several related lines of investigation.
First, epidemiological studies have pointed to an association
between n-3 and n-6 dietary intake and lifetime prevalence of
bipolar disorder. Populations that consume greater long-chain n-3s
and less long chain n-6s have a lower incidence of bipolar disease
[8]. Second, animal studies have shown that diets deficient in n-3s
alter monoamine systems in limbic structures known to control
mood (reviewed by Chalon [9]), which provides a possible
mechanistic link to psychiatric disorders. Third, mood stabilizers
commonly used to treat bipolar disorder specifically inhibit
membrane turnover and downstream signaling of the n-6 fatty
acid, arachidonic acid (AA), but not the n-3, DHA [10]. Both
lithium and carbamazepine decrease expression of phospholipase
A2, responsible for cleaving AA from the membrane. Additionally,
lithium, carbamazepine, valproate and lamotrigine inhibit COX2
expression, responsible for processing AA into the prostaglandin
E2 series signaling molecules. These data suggest that mood
stabilizers tip the scales in the direction of n-3 activity, by
inhibiting AA function and reducing competition with DHA and
EPA. Furthermore anti-depressants that increase AA activity in
rodents (e.g. imipramine), have a higher probability of inducing
mania in human bipolar subjects [11]. These data are consistent
with the hypothesis that low n-3 or high n-6 tissue concentration
may destabilize mood and suggest that the tissue balance between
competing n-3 and n-6 fatty acid species may play a role in the
pathoetiology of bipolar disorder.
The n-3 and n-6 PUFA are essential in the diet, since they
cannot be synthesized de novo by mammals. Technically, we only
need to obtain the n-3, alpha linolenic acid (ALA), and the n-6,
linoleic acid (LA), from dietary sources to synthesize longer chain
n-3 and n-6 lipids from those (Figure 1). However, studies have
shown that humans are inefficient at converting short to long
chain fatty acids and thus the tissue composition of all n-3 and n-6
lipids partially reflects dietary consumption [12]. Single nucleotide
polymorphisms (SNPs) in fatty acid desaturase (FADS) genes,
partially responsible for metabolic inter-conversion, influence n-3
and n-6 serum levels as well [13], defining a diet x gene interaction
in the control of fatty acid serum profiles and, potentially, factors
related to psychiatric illness.
Following absorption, n-3 and n-6 fatty acids compete with each
other for esterification and incorporation into cellular membranes,
where they can affect the local microenvironment. In neurons,
higher concentrations of DHA increase membrane fluidity and
receptor kinetics [14]. The n-3, EPA, and the n-6, AA, also
compete with each other for processing to various eicosanoids,
which often have opposing physiological functions relative to
immune inhibition or activation, respectively. Furthermore, the
activity of the FADS1, FADS2 and elongase enzymes (depicted in
Figure 1) can also control the available pools of short chain or long
chain fatty acids, providing a level of competition within each of
the n-3 or n-6 classes as well.
Therefore, to fully understand the efficacy of n-3 and n-6 fatty
acids in bipolar depressive illness we will need an understanding of
the subjects’ complete lipid profiles and the ratios between
competing lipids and their possible influence on various burdens
of disease. The current report explores the relationship between
PUFA profiles and personality factors, which themselves have
associated with bipolar disorder and global functioning in bipolar
subjects ([15,16]). We analyzed plasma profiles of n-3 and n-6 fatty
acid species in 27 well-characterized bipolar subjects and deter-
mined association with personality factors and suicidal history.
Given prior literature discussed above that n-3 intake inversely
associates with violent behavior and suicidality, we hypothesize
that serum levels of the long chain n-3s, DHA and EPA, may
positively associate with personality factors that may be protective
against suicide behavior and/or negatively associate with person-
ality factors that, themselves, associate with increased risk of
suicide behavior. We also hypothesize that the n-6s, linoleic acid
and arachidonic acid, may modify the relationship between n-3s
and psychiatric measures and that physiologically relevant ratios
on n-3s and n-6 may be important to consider in the analyses.
Results
In assessing the relationship between the five personality factor
scores and n-3, n-6 fatty acids, we found that the relative plasma
concentrations of several lipid species or physiologically relevant
ratios between lipid species significantly correlated with various
personality factors. Because of the pilot nature of this study,
multiple testing corrections were not applied, however, all test are
reported in Table 1. We found twice the number of significant
correlations, below the 5% type I error threshold, than would be
predicted by chance. However, independence of the tests cannot
be assumed and we found a clustering of significant findings of
associations between EPA (relative to it’s precursor and product)
and personality factor scores.
Figure 2 shows Pearson correlations revealing that the
ALA:EPA ratio negatively correlated and the EPA:DHA ratio
positively correlated with extraversion (p=0.045, r=20.389 for
ALA:EPA; p=0.048, r=0.384 for EPA:DHA) and agreeableness
(p=0.023, r=20.436 for ALA:EPA; p=0.024, r=0.433 for
Figure 1. Schematic of biosynthetic pathway for common n-3
and n-6 fatty acids. Major dietary inputs are shown with arrows and
enzymes catalyzing each conversion are given.
doi:10.1371/journal.pone.0029297.g001
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to its precursor, ALA, and its downstream product, DHA,
associate with extraversion and agreeableness. The correlations
with agreeableness remained significant following correction for
age, BMI and antipsychotic medication dose.
Figure 3 shows that the ALA:DHA ratio negatively correlated
with openness factor score (p=0.008, r=20.498) and FADS2
activity positively correlated with openness factor score (p=0.036,
r=20.406). These data suggest that more efficient conversion of
the 18 carbon ALA to the 22 carbon DHA (partially dependent on
FADS2 activity) may associate with increased openness to
experience. These data remained significant following correction
for age, BMI and antipsychotic medication dose (Table 1).
In an analysis that compared lipid species in bipolar patients
with and without a history of suicide, we found a significantly
lower serum AA concentration (p=0.026) and a trend for lower
EPA serum concentrations (p=0.070) in suicide attempters, as
shown in figure 4a. After correcting for age, BMI and
antipsychotic medication use, the difference in AA serum
concentration between the suicide attempters and non-attempters
remained significant (p=0.037).
Discussion
Identifying metabolic or dietary factors that influence factors
associated with psychiatric illness may provide a path to improving
therapeutic tools. In previous studies, an effect of n-3 fatty acid
supplementation has shown inconsistent association with improve-
ments in bipolar symptomology ([7]) and we suggest that this may
be due to variable concentrations of other lipid species, either n-6
fatty acids that tend to compete with n-3 fatty acids in a variety of
signaling, inflammatory and other pathways; or genetically variant
enzyme activities that favor pooling one fatty acid over another. In
this report, we found that n-3 and n-6 lipid profiles correlate with
aspects of the five factor personality model that have themselves
been associated with suicidal behavior ([16,17,18]). This does not
imply a relationship between PUFA profiles and suicide. However,
given prior literature on such a potential relationship ([19]), the
current study contributes to a warranting of further investigation
into the relationship between the various components of suicide
risk and PUFA profiles.
Without a control population in the current study, it is
impossible to state whether or not the association between PUFA
profiles and personality factors is specific to a psychiatric
population. However, this is not our purpose. If PUFA profiles
influence personality factors, like agreeableness and extraversion,
this may be one additional risk factor for suicidal behavior in
psychiatric patients, like bipolars, who are already at increase risk
for suicide. An association between PUFA profiles and personality
factors may also exist in a healthy population, but without
significant consequence. Larger studies with a control population
are necessary to answer these questions.
We also found associations between lipid profiles and suicidal
history in bipolar subjects. These data further support a link
between essential fatty acid metabolism and mood disorders.
While the current pilot study is an observational, cross-sectional
study, it raises important questions regarding potential causative
roles for lipid profiles in regulating personality phenotypes that
may impact the treatment of bipolar disorder. We are cognizant of
the fact that personality factors, promoted as trait markers in
bipolar disorder are not entirely stable [20] and longer-term
longitudinal studies are necessary to examine the relationship
between personality traits and fatty acid profiles.
In the current study, we found that DHA:ALA ratios and
FADS2 activity (which promotes DHA synthesis) significantly
correlated with openness personality factors, correlations that
Figure 2. Scatter plots of ALA:EPA ratio, EPA:DHA ratio and both agreeableness and extraversion factor scores. Graphs show
significant correlations between ALA:EPA and agreeableness (p=0.023, r=20.436) and extraversion (p=0.045, r=20.389) and significant positive
correlations between EPA:DHA and agreeableness (p=0.024, r=0.433) and extraversion (p=0.048, r=0.384).
doi:10.1371/journal.pone.0029297.g002
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antipsychotic medication dose. These data suggest that the
conversion from short chain ALA to long chain DHA, which is
moderated by both dietary and genetic factors that control FADS1
and FADS2 activity, associate with openness, which itself is
positively associated with suicidal risk in bipolar subjects [21].
Therefore, this provides one point where dietary input and n-3
metabolism may interact to contribute to the regulation of
personality factors that influence suicidal behavior. Future
prospective studies are required to clarify whether there is a
causal role for dietary PUFA that can be manipulated to reduce
suicide risk.
In support of this EPA:ALA and EPA:DHA ratios correlated
with agreeableness and this association also remained significant
following correction for age, BMI and antipsychotic medication
dose. Thus, a higher pool of EPA relative to its precursor ALA or
its product DHA, which would be promoted by lower FADS2
activity, associated with higher agreeableness factor scores.
Previously, higher agreeableness scores have been shown to be
protective against suicidal behavior [18].
Finally, we found that the long chain n6, AA, was lower in
subjects with a history of suicide attempt, suggesting that increased
serum concentrations of this PUFA may be protective. This is
consistent with prior literature associating suicidal behavior with
decreased serum lipids, including cholesterol, although this is
controversial [22]. Higher AA pools would also be promoted by
lower FADS2 activity, since this enzyme promotes the conversion
of AA to longer chain lipids. These data may seem paradoxical
since one would expect the activity of the n-3 fatty acids, EPA and
DHA to be lower due to competition with increased AA. However,
in an analysis that looked at AA to DHA, AA to EPA and total n-6
to total n-3 ratios, we found that all of these ratios were higher in
subjects with a history of suicide, suggesting a complex relationship
between absolute and relative AA concentration as a risk factor for
psychiatric illness. These data are not presented because they did
not reach statistical significance, potentially due to the low power
of the current study.
Taken together, these data suggest that increased activity of
FADS2, which is genetically moderated with known SNP
variants that control serum lipid profiles [13], may increase
the risk of suicidal behavior in bipolar subjects. Referring to
figure 1, increased activity of FADS2 would reduce the pool of
both AA and EPA by promoting conversion to longer chain
fatty acids shown in both the n-3 and n-6 pathways. We found
the increased FADS2 activity and several consequences of
Figure 3. Scatter plot of openness factor score and (a) serum
ALA:DHA ratio or (b) FADS2 activity. Graphs show a significant
negative correlation between openness factor score and serum
ALA:DHA ratio (p=0.008, r=20.498) and a significant positive
correlation between openness factor score and FADS2 activity
(p=0.036, r=20.406).
doi:10.1371/journal.pone.0029297.g003
Figure 4. Bar graph of differences in serum AA concentration
between subjects with and without a history of suicide
attempt. Serum AA is plotted for both suicide attempters and non-
attempters; error bars show standard deviation (p=0.026).
doi:10.1371/journal.pone.0029297.g004
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DHA:EPA, decreased EPA:ALA and reduced AA serum
concentrations, all associated with markers of increased suicidal
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expression has been previously reported in the prefrontal cortex
of bipolar subjects [23], a brain region that influences mood
circuitry.
Limitations of this study include a small sample size, a
clinically diverse group (regarding current status and medication
history) and the lack of a healthy control group to make
comparisons, which all limit the statistical power of the study
and ability to extrapolate to a larger population. Furthermore,
the lack of multiple testing correction requires the data be
examined cautiously and the need for confirmation in larger
sample sets with the added power to analyze SNP variants
directly. This will be the focus of our future investigations.
However, our results focused on EPA are consistent with prior
literature implicating this PUFA in mood regulation and raises
interesting questions as to whether specific SNPs in the FADS
genes and other lipid metabolism control points may be useful in
guiding PUFA dietary or supplementation strategies that could
augment the treatment of bipolar patients through dietary
approaches.
Materials and Methods
Bipolar disorder subjects, receiving an atypical antipsychotic
(olanzapine, quetiapine, risperidone or clozapine) were recruited
for this cross-sectional study, as reported previously [24]. After
informed consent was obtained, subjects underwent metabolic
screening and fasted blood samples were drawn and used for
lipomic analysis. All recruitment, enrolling and data analysis were
done with the approval of the Institutional Review Board for
human subject use at the University of Michigan and written
consent for the studies was obtained from all subjects. Medical and
demographic data for the subjects are summarized in Table 2,
separated into suicide attempter and non attempter groups.
Total fasted plasma lipid profiles were obtained from 27 bipolar
subjects who were dual enrolled in a second study, for which
detailed psychiatric data were available. Total lipids were
extracted from the plasma according to the method of Bligh and
Dyer [25]. Heptadecanoic acid internal standard for lipid sub-
classed was added to each sample prior to extraction. After
hydrolysis, lipids were methylated and analyzed on an Omega
Wax 250 capillary column (Supelco) using an Agilent 6890 gas
chromatograph. Relative abundance of 22 different naturally
occurring fatty acid and 3 trans-fatty acid species were done by
Table 2. Subject Data.
Age Gender Current AAP Dose (mg/day) CPZ eqs. BMI Suicide Hx
53 F Quetiapine 300 170.9 25 No
51 F Quetiapine 12.5 7.1 25 No
57 F Quetiapine 600 341.9 21 No
64 M NA NA 0.0 32 No
26 F Aripiprazole 5 62.7 22 No
56 F Aripiprazole 20 250.9 45 No
51 F Quetiapine 400 227.9 33 No
45 M Quetiapine 600 341.9 38 No
58 F Quetiapine 100 57.0 33 No
61 F Risperidone 4 332.1 29 No
22 F Aripiprazole 7.5 94.1 22 Yes
47 F Clozapine 200 144.1 26 Yes
33 F Paliperidone 3 38 Yes
54 M Aripiprazole 15 188.2 33 Yes
50 M Aripiprazole 25 313.6 24 Yes
25 F Risperidone 2 166.0 21 Yes
25 F NA NA 0.0 39 Yes
42 F NA NA 0.0 20 Yes
60 M Quetiapine 125 71.2 30 Yes
42 M Risperidone 2 166.0 31 Yes
38 M Olanzapine 7.5 140.7 30 Yes
37 F Quetiapine 25 14.2 35 Yes
56 F Risperidone 1 83.0 33 Yes
42 F Olanzapine 15 281.5 35 Yes
56 F NA NA 0.0 29 Yes
54 F NA NA 0.0 43 Yes
35 F Ziprasidone 160 255.5 23 Yes
Atypical antipsychotic (AAP) medications are given with actual dose and chlorpromazine equivalents (CPZ eqs.). Body mass index (BMI) and history of suicide attempt
(Suicidal Hx), either Yes or No are also reported.
doi:10.1371/journal.pone.0029297.t002
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activity estimates were calculated using the ratio of 18:3 (n-6) to
18:2 (n6).
The revised NEO personality inventory (NEO-PI-R) was used
to measure the five personality factor scores (neuroticism,
extraversion, openness, agreeableness and conscientiousness). We
chose to normalize the NEO-PI-R data to the S-Form and all
factors were calculated as per the NEO-PI-R manual [26]. (NEO
PI-R professional manual. Odessa, FL: Psychological Assessment
Resources, Inc.). Suicidal history was extracted from a clinician
directed interview using the Diagnostic Interview for Genetic
Studies (DIGS, [27]). All subjects were also completed a Young
Mania Rating Scale and a Hamilton Depression Scale on the same
day as the NEO-PI. Twenty one subjects showed no signs of mania
(score,8), 4 showed a slight increase in mania (score 9–11), one
showed moderate mania (score=16) and one showed elevated
mania (score=33). Fifteen showed no depression (score,8), 8
showed minor depression (score 9–15), and 4 showed moderate
depression (score 16–20).
Data were analyzed with SPSS 19 software (IBM) using a
bivariate correlation analysis for the lipid concentration - person-
ality factor score correlations; and linear multivariate analysis for
group comparisons between suicide attempter and non-attempter
groups, using age, BMI and antipsychotic medication dose
(normalized to chlorpromazine equivalents by the method of
Andreasen, et al. [28]) as covariates in the model.
Author Contributions
Conceived and designed the experiments: SJE. Performed the experiments:
SJE VLE CFB. Analyzed the data: SJE VLE CFB ARP MK. Contributed
reagents/materials/analysis tools: SJE ARP GJH MGM VLE MK CFB.
Wrote the paper: SJE.
References
1. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, et al. (2005)
Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the
National Comorbidity Survey Replication. Arch Gen Psychiatry 62: 593–602.
2. Novick DM, Swartz HA, Frank E (2010) Suicide attempts in bipolar I and
bipolar II disorder: a review and meta-analysis of the evidence. Bipolar Disord
12: 1–9.
3. Gitlin M (2006) Treatment-resistant bipolar disorder. Mol Psychiatry 11:
227–240.
4. Huan M, Hamazaki K, Sun Y, Itomura M, Liu H, et al. (2004) Suicide attempt
and n-3 fatty acid levels in red blood cells: a case control study in China. Biol
Psychiatry 56: 490–496.
5. De Vriese SR, Christophe AB, Maes M (2004) In humans, the seasonal variation
in poly-unsaturated fatty acids is related to the seasonal variation in violent
suicide and serotonergic markers of violent suicide. Prostaglandins Leukot Essent
Fatty Acids 71: 13–18.
6. Hibbeln JR, Umhau JC, Linnoila M, George DT, Ragan PW, et al. (1998) A
replication study of violent and nonviolent subjects: cerebrospinal fluid
metabolites of serotonin and dopamine are predicted by plasma essential fatty
acids. Biol Psychiatry 44: 243–249.
7. Turnbull T, Cullen-Drill M, Smaldone A (2008) Efficacy of n-3 fatty acid
supplementation on improvement of bipolar symptoms: a systematic review.
Arch Psychiatr Nurs 22: 305–311.
8. Hibbeln JR, Nieminen LR, Blasbalg TL, Riggs JA, Lands WE (2006) Healthy
intakes of n-3 and n-6 fatty acids: estimations considering worldwide diversity.
Am J Clin Nutr 83: 1483S–1493S.
9. Chalon S (2006) N-3 fatty acids and monoamine neurotransmission.
Prostaglandins Leukot Essent Fatty Acids 75: 259–269.
10. Rapoport SI, Basselin M, Kim HW, Rao JS (2009) Bipolar disorder and
mechanisms of action of mood stabilizers. Brain Res Rev 61: 185–209.
11. Lee HJ, Rao JS, Chang L, Rapoport SI, Kim HW (2009) Chronic imipramine
but not bupropion increases arachidonic acid signaling in rat brain: is this related
to ‘switching’ in bipolar disorder? Mol Psychiatry 15: 602–614.
12. Arterburn LM, Hall EB, Oken H (2006) Distribution, interconversion, and dose
response of n-3 fatty acids in humans. Am J Clin Nutr 83: 1467S–1476S.
13. Glaser C, Heinrich J, Koletzko B (2010) Role of FADS1 and FADS2
polymorphisms in polyunsaturated fatty acid metabolism. Metabolism 59:
993–999.
14. Gawrisch K, Soubias O, Mihailescu M (2008) Insights from biophysical studies
on the role of polyunsaturated fatty acids for function of G-protein coupled
membrane receptors. Prostaglandins Leukot Essent Fatty Acids 79: 131–134.
15. Kim B, Joo YH, Kim SY, Lim JH, Kim EO (2011) Personality traits and
affective morbidity in patients with bipolar I disorder: the five-factor model
perspective. Psychiatry Res 185: 135–140.
16. Brezo J, Paris J, Turecki G (2006) Personality traits as correlates of suicidal
ideation, suicide attempts, and suicide completions: a systematic review. Acta
Psychiatr Scand 113: 180–206.
17. Janowsky DS (2001) Introversion and extroversion: implications for depression
and suicidality. Curr Psychiatry Rep 3: 444–450.
18. McCann SJ (2010) Suicide, big five personality factors, and depression at the
American state level. Arch Suicide Res 14: 368–374.
19. Hibbeln JR (2009) Depression, suicide and deficiencies of n-3 essential fatty acids
in modern diets. World Rev Nutr Diet 99: 17–30.
20. Barnett JH, Huang J, Perlis RH, Young MM, Rosenbaum JF, et al. (2010)
Personality and bipolar disorder: dissecting state and trait associations between
mood and personality. Psychol Med. pp 1–12.
21. Allen MH, Chessick CA, Miklowitz DJ, Goldberg JF, Wisniewski SR, et al.
(2005) Contributors to suicidal ideation among bipolar patients with and without
a history of suicide attempts. Suicide Life Threat Behav 35: 671–680.
22. De Berardis D, Conti CM, Serroni N, Moschetta FS, Carano A, et al. (2009)
The role of cholesterol levels in mood disorders and suicide. J Biol Regul
Homeost Agents 23: 133–140.
23. Liu Y, McNamara RK (2011) Elevated Delta-6 desaturase (FADS2) gene
expression in the prefrontal cortex of patients with bipolar disorder. J Psychiatr
Res 45: 269–272.
24. Ellingrod VL, Taylor SF, Dalack G, Grove TB, Bly MJ, et al. (2011) Risk
Factors Associated with Metabolic Syndrome in Bipolar and Schizophrenia.
J Clin Psychopharm In Review.
25. Bligh EG, Dyer WJ (1959) A rapid method of total lipid extraction and
purification. Can J Biochem Physiol 37: 911–917.
26. Costa PT, McCrae RR (1992) NEO PI-R professional manual. Odessa, FL:
Psychological Assessment Resources, Inc.
27. Nurnberger JI, Jr., Blehar MC, Kaufmann CA, York-Cooler C, Simpson SG,
et al. (1994) Diagnostic interview for genetic studies. Rationale, unique features,
and training. NIMH Genetics Initiative. Arch Gen Psychiatry 51: 849–859;
discussion 863–844.
28. Andreasen NC, Pressler M, Nopoulos P, Miller D, Ho BC (2010) Antipsychotic
dose equivalents and dose-years: a standardized method for comparing exposure
to different drugs. Biol Psychiatry 67: 255–262.
Lipids, Personality and Suicide Risk
PLoS ONE | www.plosone.org 7 January 2012 | Volume 7 | Issue 1 | e29297